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Abstract: FAS-associated protein with death domain (FADD) is a major adaptor protein involved in extrinsic apoptosis, embryogenesis, and
lymphocyte homeostasis. Although abnormalities of the FADD/death receptor apoptotic pathways have been established in tumorigenesis, fewer studies
have analyzed the expression and role of phosphorylated FADD (pFADD). Our identification of FADD as a lymphoma-associated autoantigen in T-cell
lymphoma patients raises the possibility that pFADD, with its correlation with cell cycle, may possess role(s) in human T-cell lymphoma development.
This immunohistochemical study investigated pFADD protein expression in a range of normal tissues and lymphomas, particularly T-cell lymphomas that
require improved therapies. Whereas pFADD was expressed only in scattered normal T cells, it was detected at high levels in T-cell lymphomas (eg, 84%
anaplastic large cell lymphoma and 65% peripheral T cell lymphomas, not otherwise specified). The increased expression of pFADD supports further study
of its clinical relevance and role in lymphomagenesis, highlighting phosphorylation of FADD as a potential therapeutic target.
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Introduction

Autoantibody signatures have provided invaluable information
for assisting both in the identification and early detection of
disease.1–4 Furthermore autoantigens, such as anaplastic lymphoma kinase (ALK), which are functionally implicated in
tumor progression, represent important therapeutic targets.5,6
In a previous study, protein microarrays were screened with
sera from lymphoma patients to identify lymphoma-associated

antigens. The aim was to identify autoantigens that might
represent new tools for identifying high risk patients and/
or novel treatment options for patients with systemic
ALK-negative anaplastic large cell lymphoma (ALCL),
a provisional tumor entity with a poor prognostic outlook. The
FAS-associated protein with death domain (FADD), encoded
by a gene within 11q13, was identified as an autoantigen recognized by circulating antibodies present not only in the sera
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of patients with systemic ALCL but also in patients with
peripheral T-cell lymphoma, not otherwise specified (PTCL,
NOS), as well as B-cell lymphoma.7 PTCL, in common with
systemic ALK-negative ALCL, represents a poorly defined
lymphoma category with a poor prognostic outlook for which
improved therapies are urgently required.8
Multiple roles have been ascribed to the FADD protein.
Containing a death domain (DD) and a death effector
domain (DED), FADD is a major adaptor protein in the
extrinsic apoptotic pathway linking transduction signals from
membrane-bound death receptors, eg, CD95 and DR4, with
caspase 8.9,10 More recently, interactions of FADD with RIP1
and RIP3 have been identified, with FADD being a negative
regulator of a programmed form of necrotic cell death, known
as “necrotopsis.”11,12 FADD is also required for embryogenesis and lymphocyte proliferation via pathways that are independent of death receptor-mediated apoptosis,13–16 the DD
motif acting as a switch between apoptosis and proliferation.16
The pivotal roles of FADD in cell cycle regulation and
proliferation17,18 occur following its phosphorylation (at serine
194 in humans or serine 171 in mice) and nuclear relocalization at the G2/M stage of cell cycle.19 Nuclear pFADD may
also be involved in gene surveillance through its regulation
with human telomerase reverse transcriptase20 and its association with complexes containing the DNA repair molecules
MBD4 and MLH1.21
FADD has been associated with disease development in
humans.22–25 The amplification of the FADD gene and its correlation with increased FADD protein expression in head and
neck cancers led Gibcus et al. to describe FADD as a possible
key gene of functional interest in the 11q13 amplicon.26 Conflicting evidence has, however, been obtained on the relevance
of high levels of pFADD to patient outcome in a number of
solid tumors such as head and neck cancer, 26,27 adenocarcinoma, 22,28 gastric cancer, 29 and prostate cancer.20 Higher levels
of pFADD were, however, found to increase chemosensitization in prostate cancer cells23,30 and HeLa xenografts.31
Of relevance to the current study is that chromosomal
abnormalities of the 11q13 region, other than those associated
with Cyclin D1, have also been linked to hematological malignancies32,33 thus increasing the possibility of the involvement
of FADD in these tumor types. Since pFADD has also been
reported to correlate with proliferation in a range of B-cell
non-Hodgkin lymphomas (NHLs), 34 the current immunohistochemical study on the detection of pFADD focuses on
T-cell malignancies to determine its potential relevance as a
therapeutic target in these tumors.

Materials and Methods

Tissue samples. Normal tissues: Fresh tonsil was obtained
from patients attending the Ear, Nose and Throat Department, John Radcliffe Hospital, Oxford. Paraffin-embedded
normal tissues were obtained from the Centro Nacional de
Investigaciones Oncologicas (CNIO), Madrid.
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Hematological malignancies: Tissue microarrays (TMAs)
of a variety of lymphomas were obtained from the CNIO
while TMAs of ALK-positive and ALK-negative ALCL
and PTCL were obtained from the Department of Pathology, Wüerzburg. The 39 B-cell lymphomas consisted of
the following cases: diffuse large B-cell (DLBCL, n = 9),
mantle cell lymphoma (MCL, n = 7), follicular lymphoma
(FL, n = 7), Burkitt’s lymphoma (BL, n = 6), and Hodgkin’s
lymphoma (HL, n = 10). The 227 T-cell tumors consisted of
the following cases: PTCL (NOS) (n = 89), ALK-positive
ALCL (n = 38), ALK-negative ALCL (n = 54), angioimmunoblastic lymphoma (AITL, n = 15), angiocentric lymphoma
(n = 5), T-cell lymphoblastic lymphoma (TCL, n = 7), cutaneous T-cell lymphoma (CTCL, n = 3), T/NK lymphoma
(n = 2), mycosis fungoides (MF, n = 6), and T-cell intestinal
lymphoma (n = 8).
All normal and neoplastic cells and tissues were
obtained only after ethical approval and informed consent
had been given.
Cell lines. The Thiel (myeloma), SUDHL-1, Karpas 299
(ALK-positive ALCL), FEPD (ALK-negative ALCL). Jurkat
and CEM (T-acute lymphoblastic leukemia), U937 and HL60
(acute myeloid leukemia), germinal center – SUDHL-6,

Table 1. Expression of pFADD in normal cells and tissues.
Tissue

*pFADD distribution

Hematopoietic
Bone marrow

Megakaryocytes and occasional large blast
cells

Tonsil

Epithelium, subpopulations of germinal
center B-cells, tingible body macrophages
and subpopulations of interfollicular T and
B cells

Thymus

Subpopulations of B cells, macrophages,
epithelium, and scattered T cells

Non-Hematopoietic
Brain

No labeling detected

Thyroid

Occasional nucleus of epithelial cells

Lung

No labeling detected

Breast

No labeling detected

Colon

Subset of crypt epithelial cells

Liver

Occasional hepatocyte

Kidney

Occasional cell in tubule

Pancreas

Acinar and islet cells

Fallopian tubes

Subset of epithelial cells

Uterus

Scattered epithelial cells

Testis

Majority of spermatogonia and weak
labeling of Leydig cells.

Placenta

Scattered syncitiotrophoblast

Prostate

Subset of epithelial cells

Bladder

Epithelial cells

Note: *Nuclear staining.

FADD and pFADD in T-cell lymphomas
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Figure 1. Immunolabeling studies to show pFADD protein expression in tonsil (A–F) and thymus (G–J).
Notes: Tonsil: (A) Single immunoperoxidase labeling shows heterogeneity of pFADD expression in the nuclei of subpopulations of tonsil cells. Strong
labeling is present in a subpopulation of germinal center (gc) cells (arrowed). Scattered cells with weaker labeling are present in the mantle zone (mz)
and interfollicular (if) areas. (B) It can be seen from the double immunoperoxidase labeling studies that pFADD (brown) is heterogeneously expressed
in the majority of CD20-positive (blue) germinal center B cells (arrowed) but (C) absent from the majority of CD3-positive (blue) T cells in the germinal
center (inset, arrowed) and (D) interfollicular areas (inset, arrowed). (E) Nuclear pFADD expression (brown) is also present in the occasional CD68positive tingible body macrophage (blue, arrowed) while (F) pFADD was not detected in the interfollicular CD68-positive macrophages (arrowed).
Thymus: From (G) it can be seen that the expression of pFADD is heterogenous and limited to subpopulations of cells (arrowed) in the thymic medulla
(med) and cortex (cor). (H) pFADD was undetectable in the majority of the CD3-positive 9blue) thymocytes (inset, arrowed), pFADD was undetectable
in the majority of the CD3-positive (blue) thymocytes (inset, arrowed). (I) Strong pFADD expression (brown) was, however, detected in (I) some CD20positive B cells (blue, arrowed), (J) CD68-positive macrophages (blue, arrowed), and (K) the cytokeratin-positive (blue) thymic epithelial cells (inset,
arrowed).
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Table 2. pFADD protein expression in cell lines derived from
hematological malignancies.
Cell line

*pFADD

T-cell
FEPD

Nuclei ++ .95%

SUDHL-1

Nuclei + .95%

Karpas 299

Nuclei heterogenous +/++ .50%

Jurkat

Nuclei ++ .90%

CEM

Nuclei/cytoplasm ++ ,50% cells

B-cell
SUDHL-6

Nuclei + .75%

SUDHL-10

Nuclei ++ 90%

RIVA

Nuclei + 20%

HLY-1

Nuclei +/- 80%

HBL-1

Nuclei + 40%

Thiel

Nuclei +/- 1%

Myeloid/megakaryotic
K562

Nuclei/cytoplasm ++ ,95%

HL60

Nuclei/cytoplasm ++ ,95%

U937

Nuclei/cytoplasm ++ ,95%

HEL

Nuclei/cytoplasm ++ ,95%

Notes: *Cytoplasmic and nuclear intensity of labeling is as follows:
++ = strong, + = moderate and +/- = weak, % refers to proportion of cells
labeled. FEPD – ALK-negative anaplastic large cell lymphoma; SUDHL-1
and Karpas 299 – ALK-positive anaplastic large cell lymphoma; Jurkat and
CEM – T-acute lymphoblastic leukemia; SUDHL-6 and SUDHL-10 – germinal
center-derived diffuse large B-cell lymphoma; RIVA and HBL-1 – non-germinal
center-derived diffuse large B-cell lymphoma; Thiel – myeloma; K562 –
chronic myeloid leukemia; U937 and HL60 – acute myeloid leukemia; HEL –
megakaryocytic-derived cell lines.

SUDHL-10, and nongerminal center RIVA and HBL-1
(DLBC)-derived cell lines used were obtained and cultured
as previously described.5 The cultured cells were used to produce cytocentrifuge preparations, cell pellets, or fixed in 10%
formal-saline for paraffin embedding for the preparation of
tissue sections of the cell lines.
Antibodies. Monoclonal antibodies: Mouse monoclonal
antibodies to CD8 (C8/144), CD45RA (4KB5), and CD68
(KP1) were produced in the authors’ laboratories. Antibodies
to CD20 (Clone L26), cytokeratins (Clones Lp34 and Clones
MNF116), and β-actin (diluted 1:100) were obtained from
DakoCytomation (Glostrup, Denmark).
Polyclonal antibodies: A rabbit polyclonal antibody to
FADD phosphorylated at Ser174 was obtained from Cell
Signalling Technology (catalog number 2781, Cambridge,
UK). Anti-CD3 (DAKO-CD3 – diluted 1:100), anti-mouse
Ig conjugated to horseradish-peroxidase (HRP) diluted 1:100,
and the Dako EnVision staining kit were obtained from
DakoCytomation.
Immunolabeling techniques. Immunoperoxidase: Cytocentrifuge preparations and cryostat sections of tonsil were
stained using a two-stage immunoperoxidase technique as
80
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previously described.5 Paraffin-embedded tissue sections
and microarrays were de-waxed, and antigen retrieval was
carried out in 50 mM Tris:2 mM EDTA pH 9.0 by microwave pressure cooking for 2 minutes. The tissue sections were
then incubated with a primary antibody for 60 minutes at
room temperature (or in the case of anti-pFADD overnight
at 4 oC) before being washed in phosphate-buffered saline
(PBS) for 5 minutes. Antibody binding was detected using
the ChemMateTM DAKO EnVisionTM Detection Kit, Peroxidase/DAB using the manufacturer’s instructions. Cells were
counterstained using hematoxylin and mounted in Aquamount
(VWR International, Lutterworth, UK).
Double immunoperoxidase labeling: pFADD staining was
performed as described above but with omission of the counterstaining step. The sections were then incubated with one
of the following: anti-CD3, anti-CD20, anti-cytokeratin,
anti-CD8, or anti-CD68 for 30 minutes at room temperature
before using the EnvisionTM anti-mouse/rabbit Dual Link
reagent. After washing in PBS for 5 minutes, the slides were
incubated with the vector SG Peroxidase (HRP) substrate kit
(Vector Laboratories, Peterborough, UK). After washing, the
slides were air-dried overnight and mounted in VectorMount
(Vector Laboratories).

Results

pFADD distribution in normal tissues. The antibody
recognizing pFADD has been used in a number of previous
studies. 22,26,34,35 Its use in the current study showed pFADD
to have a limited nuclear distribution in normal tissues, as
summarized in Table 1. Of particular interest was the differential expression of pFADD in populations of hematopoietic cells. High levels of pFADD were detected only in
subpopulations of tonsillar germinal center and interfollicular cells (Fig. 1A). Double labeling studies confirmed the
majority of these cells to be CD20-positive B cells (Fig. 1B).
In contrast, pFADD was undetectable in the majority of
the CD3-positive T cells (Figs. 1C and D), with only low
levels of pFADD observed in a minority of CD3-positive
T cells. Although a small subpopulation of CD68-positive
tingible body macrophages expressed pFADD (Fig. 1E), no
interfollicular cells were observed that were stained for both
pFADD and CD68 (Fig. 1F).
In the thymus, strong pFADD staining was limited to
subsets of cells in the medulla and cortex (Fig. 1G). Double
labeling studies showed only an occasional CD3-positive
cell to be pFADD-positive, with the majority of CD3positive T cells lacking detectable pFADD (Fig. 1H, inset,
arrowed). The remaining pFADD-positive cells included
subpopulations of CD20-positive B cells (Fig. 1I), CD68positive macrophages (Fig. 1J) as well as thymic epithelial
cells (Fig. 1K).
pFADD expression in hematological malignancies.
pFADD expression was also detected in T-cell derived as
well as B-cell and myeloid-derived cell lines. The staining was

FADD and pFADD in T-cell lymphomas
Table 3. pFADD expression in hematological malignancies.
Immunolabeling results
Total
cases

Negative

,30% positive cells
n (% total cases)

.30% positive
cells
n (% total cases)

Diffuse large B-cell lymphoma

9

2 (22%)

4 (43%)

3 (33%)

Mantle cell lymphoma

7

1 (14%)

4 (57%)

2 (29%)

Follicular lymphoma (n = 7)

7

4 (57%)

3 (43%)

0 (0%)

Burkitt lymphoma

6

B-cell lymphomas

3 (50%)

2 (33%)

1 (17%)

Hodgkin’s lymphoma Lymphocyte predominant 3

0 (0%)

1 (33%)

2 (66%)

Hodgkin’s lymphoma Mixed cellularity

2

0 (0%)

0 (0%)

2 (100%)

Hodgkin’s lymphoma Nodular sclerosis

2

0 (0%)

0 (0%)

2 (100%)

Hodgkin’s lymphoma Lymphocyte rich

3

0 (0%)

0 (0%)

3 (100%)

Peripheral T-cell lymphoma
(not otherwise specified)

89

31 (35%)

49 (55%)

9 (10%)

ALK+ Anaplastic large cell lymphoma

38

6 (16%)

8 (21%)

24 (63%)

ALK- Anaplastic large cell lymphoma

54

9 (17%)

5 (9%)

40 (74%)

Angioimmunoblastic lymphoma

15

5 (33.3%)

5 (33.3%)

5 (33.3%)

Angiocentric lymphoma

5

0 (0%)

3 (60%)

2 (40%)

T lymphoblastic

7

3 (43%)

3 (43%)

1 (14%)

Cutaneous T-cell lymphoma

3

1 (33.5%)

2 (66.5%)

0 (0%)

Mycosis Fungoides

6

3 (50%)

2 (33%)

1 (17%)

T/NK-cell lymphoma

2

0 (0%)

2 (100%)

0 (0%)

T-cell intestinal lymphoma

8

0 (0%)

3 (37%)

5 (63%)

T-cell lymphomas

nuclear and generally strong. Cytoplasmic staining was also
seen in the myeloid (K562, HL60, and U937), megakaryocytic
(HEL), and the T-acute lymphoblastic leukemia (Jurkat
and CEM) cell lines tested. The results are summarized in
Table 2.
A preliminary staining study was performed on mixed
lymphoma TMAs, and the results are summarized in Table 3.
pFADD proteins were detected across a range of B-cell lymphomas. Heterogeneity in the intensity of staining of pFADD
was also seen both within and between cases of DLBCL and
MCL (not shown).
In view of the importance of FADD in normal T-cell survival and proliferation,17 the previously reported expression of
pFADD in a number of B-cell malignancies,34 and the presence
of an anti-FADD immune response in patients with T-cell
malignancies,7 we analyzed pFADD expression in 227 T-cell
tumors, with particular emphasis on ALCL and PTCL (NOS).
The results are shown in Table 3. Strong labeling of the tumor
cells was observed in 32/38 (84%) ALK-positive and 45/54
(83%) ALK-negative ALCL. Examples of results obtained
are shown in Figures 2A and 2B. The numbers of tumor cells
expressing pFADD varied from tumor biopsy to tumor biopsy
(range 10%–99%). Moderate to weak pFADD labeling was
also observed in other T-cell tumors. A total of 58/89 (65%)

cases of PTCL (NOS) were positive for pFADD. Labeling of
more than 30% of cells was detected in 9 (10%) of these cases
while 49 (55%) cases showed less than 30% of the tumor cells
to be pFADD-positive. pFADD expression was not detected
in 31 (35%) cases of PTCL (NOS). Examples of staining are
shown in Figures 2C–2E). Heterogeneity in the levels of staining of pFADD was observed within tumors in both ALCL
and PTCL (NOS). pFADD expression was detected in a range
of other T-cell lymphomas, including 67% (10/15) AITL, 57%
(4/7) T-ALL, 50% (3/6) MF, and 66% (2/3) CTCL cases.
Additional evidence to support the dysregulation of
FADD in T-cell tumors was obtained by analyzing levels
of FADD transcripts from the publicly available Oncomine
database (www.oncomine.org). Analysis of two independent
gene expression profiling (GEP) datasets indicated that the
FADD transcripts were significantly more highly expressed in
T-cell lymphomas compared to nonmalignant T-cell populations (Fig. 3). Thus T-cell malignancies exhibit both elevated
FADD transcription and FADD phosphorylation.

Discussion

Although pFADD has been studied in a number of solid
tumors, investigations of its expression in human hematological
malignancies are limited. We previously used sera from ALCL
Biomarker Insights 2014:9
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A

B

ALK-positive ALCL

ALK-negative ALCL

ALK-positive ALCL

C

PTCL

D

PTCL

E

PTCL

Figure 2. Single immunoperoxidase labeling demonstrating pFADD expression in ALCL and PTCL (NOS).
Notes: (A) An example of a case of ALK-positive ALCL where the tumor cells express pFADD (arrowed). Note the presence of pFADD in the cytoplasm
of mitotic cells (arrowhead). The inset shows an example of a pFADD-negative case of ALK-positive ALCL. (B) Strong nuclear pFADD expression is also
present in a case of ALK-negative ALCL (arrowed). Cytoplasmic pFADD is also present in a mitotic cell (arrowhead). Different examples of pFADD in
three cases of PTCL are shown in (C–E). While the majority of tumor cells are pFADD-positive (arrowed) in (C), the percentage drops to less than 30% in
(D) while the PTCL in (E) lacks detectable pFADD.

patients to screen a protein microarray containing more than
12,000 different proteins with the aim of identifying lymphoma-associated antigens that could identify high-risk patients
or that might represent novel therapeutic targets. Four antigens, FADD, transcription elongation factor A protein-like 2
(TCEAL2), lipid phosphate phosphate-related protein type 3
(LPPR3), and ribonuclease T2 (RNASET2), were identified
as ALK-negative ALCL-associated autoantigens. Further validation studies also confirmed FADD, TCEAL2, and RNASET2 to be PTCL-associated autoantigens recognized by
circulating antibodies in patients.7 This result, combined with
the interest in the role of pFADD in oncogenesis, indicated the
importance of performing an immunohistochemical study of
pFADD protein expression, in a range of T-cell lymphomas.
High levels of pFADD protein had a limited distribution in normal tissues and were restricted to the nucleus. These
results are in agreement with previous studies reporting nuclear
pFADD protein in subpopulations of human gastric epithelial
cells, hepatocytes, kidney, and tonsillar cells.28,29,34,36 The current study using double labeling techniques is, however, the
first not only to confirm high levels of pFADD expression
in subpopulations of normal CD20-positive B cells but also
to identify the absence or restricted low-level expression of
pFADD in normal tonsillar T cells and thymocytes. Since the
82
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presence of pFADD has been linked to T-cell activation and
proliferation in human cell lines and in mice,17,18,37 the lack of
pFADD in T cells in the current study suggests that there are
only low numbers of activated T cells in the G2/M stage of
cell cycle in normal tonsil and thymus.
pFADD was observed in B-cell-derived cell lines and
tumors, a result in keeping with a previous study where
pFADD expression was found to correlate with the proliferation of B-lymphoma cells.34 pFADD expression was, however,
also detected in a wide variety of T-cell leukemia-derived cell
lines and in primary T-cell lymphoma biopsies. 65% PTCL
(NOS) and 83% ALCL expressed levels of pFADD. No significant difference was found between ALK-positive and ALKnegative ALCL, with high levels of pFADD being detected
in 84% and 83% of ALK-positive and ALK-negative ALCL,
respectively. Although pFADD protein expression was previously reported in ALCL and CTCL, Clarke et al investigated
only nine cases of ALCL and three cases of CTCL. 36 The
increased expression of pFADD protein in T-cell malignancies compared to normal T-cells studied here suggests that
pFADD is accumulated possibly as a result of the constitutive
activation of the tumor cells. The increase in pFADD could
also result from increased expression of FADD or its increased
phosphorylation as part of the disease process. The evidence

FADD and pFADD in T-cell lymphomas
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Figure 3. FADD transcript expression in T-cell lymphomas and ALCL.
Notes: FADD transcript was expressed at significantly higher
levels in T-cell lymphomas than in nonmalignant T-cell populations
in two independent gene expression profiling datasets: (A) normal
T-lymphocytes, n = 31; ALCL (anaplastic large cell lymphoma), n = 9
(five cases of ALK-positive ALCL and four cases of ALK-negative
ALCL);38 and (B) normal T-lymphocytes, n = 20 (including five samples
each of CD4-positive and CD8-positive T-lymphocytes); ALCL, n = 6;
AITL (angioimmunoblastic T-cell lymphoma), n = 6; PTCL (NOS)
(peripheral T-cell lymphoma, not otherwise specified), n = 28.8

from two GEP datasets8,38 (shown in Fig. 3), where increased
levels of FADD transcripts were observed in PTCL, AITL,
ALK-positive and ALK-negative ALCL, compared to normal
T cells, suggests that the increased pFADD protein expression
in some patients is likely to reflect the upregulation of FADD
transcription and thus, most likely, increased FADD protein.
A major factor in lymphoma growth is resistance to apoptosis. Examples include abnormalities in the Fas/FasL and CD30mediated apoptotic pathways as well as c-FLIP overexpression
in T-cell lymphomas such as ALK-positive ALCL,39 and ALKnegative tumors such as CTCL and mycosis fungoides.40,41 It is
possible that re-localization of FADD to the nucleus following its
phosphorylation19,42 may play a major role in the dysregulation of
apoptosis in human lymphomas as reported for murine T-ALL.43
pFADD overexpression has also been linked to increased activity of the anti-apoptotic NF-κB protein.22,44 and activation of
the c-jun NH2-terminal kinase (JNK) signaling pathway,24,30
both of which are implicated in T-cell lymphomagenesis.45,46
Aberrant pFADD expression has also been linked with proliferation in human B-cell lymphomas34 and to cell cycle defects in
murine T cells,37 with hematopoietic as well as solid tumor cells
arresting at the G2/M stage.18,19,23,24
Further investigations are required to determine the prognostic relevance of pFADD in T-cell malignancies, which
has been linked with varying outcomes in malignancies in

other studies. Increased levels of pFADD and NF-κΒ have
been linked to poorer survival in head and neck 26 and lung
cancers,22,28 while others have described low pFADD expression to be associated with poorer prognosis in myeloid leukemia.47 There is also a reported link between higher levels of
pFADD and improved local tumor control in early stage larynx
cancer27 and prostate cancer.20 Of interest is that the increased
transition from FADD to pFADD has been associated with an
improved sensitivity to treatment with chemotherapy in prostate cancer23,30 and radiotherapy in head and neck cancer.27
Although ALK-positive ALCL is associated with a
good prognosis,48 the same cannot be said for ALK-negative
ALCL and PTCL-NOS, and improved therapies are urgently
needed for these lymphomas.49–52 FADD and its interacting
proteins, such as RIP1, are expressed in both ALK-negative
and ALK-positive ALCL53 and may thus represent exciting
therapeutic targets. Although there is evidence for a tumor
suppressor role of pFADD in nonhematological tumors, 31
it will be important to study further the biological activity
of pFADD in T-cell malignancies. Of interest was a report
that a novel inhibitor of FADD phosphorylation resulted in
decreased levels of the anti-apoptotic NF-κΒ,44 a factor implicated in lymphogenesis,54 suggesting the potential of pFADD
as a therapeutic target in T-cell malignancies.
In conclusion, the results from the current study provide
the first detailed immunohistochemical study of the expression of pFADD in normal tissues and hematological malignancies, with particular emphasis on T-cell tumors. The
increased expression of pFADD observed in T-cell lymphomas
not only suggests a possible role in lymphoma development
but also further highlights phosphorylation of the lymphoma-associated autoantigen FADD as a potential therapeutic
target.
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